Cost blocks public access to RSV protection for babies
Image: Mail & Guardian
High costs are preventing newly approved maternal vaccines and antibody treatments for RSV from entering South Africa's public healthcare system, leaving vulnerable infants without protection.
Read the full story on Mail & Guardian →
News24x7 shows the headline and a short extract only. The full article, its images and all rights belong to Mail & Guardian.